-
Sector Analysis
Colorectal Cancer - Global Drug Forecast and Market Analysis to 2028
Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche’s Avastin, and epidermal growth factor receptor (EGFR) inhibitors. GlobalData valued the CRC market at $7.6B in 2018. This market is...
-
Sector Analysis
Prostate Cancer - Global Drug Forecast and Market Analysis to 2028
The prostate cancer market in the 8 major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) is expected to experience a moderate growth between 2018 and 2018. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone naïve (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide). Until recently, the hormone...
-
Sector Analysis
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025
Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC,...
-
Sector Analysis
Melanoma – Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic...
-
Sector Analysis
B-Cell Non-Hodgkin’s Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2027
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers...
-
Sector Analysis
Pancreatic Cancer: Opportunity Analysis and Forecast to 2026
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer, despite accounting for only 3% of new cancer diagnoses. Patients with advanced pancreatic cancer have a median survival of approximately 2.8–5.7 months, even in light of recent therapeutic innovations and elucidation of fundamental biological mechanisms of the disease. In the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) approximately two-thirds of patients are diagnosed with...
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2026
The head and neck (HNC) cancer market is expected to experience significant growth between 2016 and 2026 within the seven major markets (US, France, Germany, Italy, Spain, UK and Japan). The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market. Up until the approvals of Opdivo...
-
Sector Analysis
Myelodysplastic Syndromes - Opportunity Analysis and Forecasts to 2028
Myelodysplastic syndromes (MDS) are a relatively rare group of acquired clonal hematopoietic stem cell disorders characterized by dysfunctional hematopoiesis leading to cytopenias, with the potential to transform into acute myeloid leukemia (AML). DNA damage and mutations are the predominant factors contributing to MDS development and progression. As such, aging and the associated accumulation of mutations over time appear to be the most important risk factors for the disease. Clonal shifts in hematopoietic stem and progenitor cells due to mutations, cytogenetic...
-
Sector Analysis
Bladder Cancer - Opportunity Analysis and Forecasts to 2028
The bladder cancer market in the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is expected to experience a high growth between 2018 and 2028. The main drivers of growth will be an increased incident patient population, continued uptake of immunotherapy drug and targeted therapy regimen in the metastatic patient, and the launch and uptake of 11 new premium-priced therapies along with label expansion of PD-1/PD-L1 inhibitors, including the newly approved Balversa (erdafitinib), and Padcev (enfortumab...
-
Sector Analysis
Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029
Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.